Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections

• Status: Unknown status
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Adult patients with ESBL-producing Gram negative infections are randomized to receive ertapenem or meropenem/imipenem. Clinical and microbiological responses between both groups are compared.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mahidol University
• Treatments: Ertapenem; Imipenem; Meropenem; Thienamycins

Criteria

Inclusion Criteria:

• Hospitalized patients aged >18 years with documented ESBL +ve GNB infection

• Receive meropenem or imipenem/cilastatin as empiric antibiotic therapy

Exclusion Criteria:

• Having been treated with meropenem or imipenem/cilastatin for longer than 72 hours

• Have active P. aeruginosa co-infection

• Pregnancy or breast feeding

• Allergy to carbapenems